Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

Latest News - James Carthew

Carthew: revisiting the most newsworthy trusts of 2017

As 2018 gets underway, I thought that it might be worth revisiting some of the funds that I wrote about in 2017.

Carthew: trusts offering Woodford a lesson in buying AIM minnows

A couple of weeks ago, I was writing about the potential dangers of holding too many early stage and loss-making technology companies in a portfolio

Carthew: the fliers and flops of the trust class of 2017

It has been a fairly busy year for new issues and we still might see a few more make it over the finish line before Christmas

Carthew: Woodford has too many eggs in too few baskets

In a world of quite binary outcomes, diversification seems like a good idea to me.

Carthew: who is next in Bramson's £700m sights?

At the beginning of July 2017, Sherborne Investors C raised £700 million to fund its next battle

James Carthew: is the Japanese glass half full, empty, or illusory?

It is easy to become fixated on Japan's macroeconomic picture.

Carthew: how multi-manager needs to evolve to survive

It has been 10 years since Princess Private Equity listed in London.

Carthew: Biopharma trusts can't resist the double dip

The size and depth of opportunities in healthcare continue to expand

Carthew: complexity killed the ZDP stars

On the face of it, the zero dividend preference market is fading away

Carthew: wait for Brexit blood in the streets to buy property

Why is Hansteen offering to buy back half its issued shares at a premium?